GSVA revealed that cell cycle-related pathways (e.g., MYC target and G2/M checkpoint), immune response pathways (e.g., IL-2 STAT5 signaling and TNF signaling via NF-κB), and aberrantly activated pathways (e.g., mTORC1 and PI3K/AKT/mTOR signaling) were dominant in tumor cells of APHC. The gene discussed is ACER3; the disease is neoplasm.